SEPTInvestingStart Free

ALGS 10-Q: SEC filing

Aligos Therapeutics

Filed with the SEC on · accession 0001193125-26-450798

ALGS filed a 10-Q (quarterly report) with the SEC on Nov 6, 2026. Aligos Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results including R&D and G&A expenses, license and collaboration agreements (Amoytop, Emory, KU Leuven), and equity/warrant activity. The stock moved -9.5% by the first close after the filing.

Summary of the filing

Aligos Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results including R&D and G&A expenses, license and collaboration agreements (Amoytop, Emory, KU Leuven), and equity/warrant activity. No single major corporate event is disclosed.

For details, click here →How to read a 10-Q →

Key details

License and research collaboration partnerAmoytop
License agreement counterpartyEmory University
License agreement counterpartyKatholieke Universiteit Leuven
Letter of credit counterpartyBritannia Biotech Gateway Limited Partnership

How ALGS stock reacted

Close before

$4.51

Nov 5, 2026

First close after

-9.53%

$4.08

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ALGS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ALGS?

Click here

Frequently asked questions

What did ALGS file with the SEC on Nov 6, 2026?

ALGS filed a 10-Q (SEC filing). Aligos Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results including R&D and G&A expenses, license and collaboration agreements (Amoytop, Emory, KU Leuven), and equity/warrant activity. No single major corporate event is disclosed.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did ALGS stock react to this filing?

ALGS closed at $4.51 before the filing and $4.08 on Nov 6, 2026 (-9.53%).

Other ALGS SEC filings

Get alerts when ALGS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ALGS overviewALGS analysisALGS newsLatest SEC filings